Fig. 3
Cost-effectiveness acceptability curves of nivolumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy. QALY, quality-adjusted life year.
Fig. 3 | Scientific Reports
Cost-effectiveness acceptability curves of nivolumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy. QALY, quality-adjusted life year.
